AB095

AB095 is an anti-tetanus toxoid antibody fragment (scFv or Fab) that serves as a negative control or "null" targeting arm in the development of multispecific immune cell engagers. Developed by AbbVie and utilized in collaboration with Dragonfly Therapeutics, AB095 is designed to bind an antigen not present in human tissues, thereby allowing researchers to isolate and measure target-independent biological activity, such as non-specific immune activation or Fc-mediated effects. It is a critical research tool in the preclinical validation of platforms like TriNKET (e.g., ABBV-303) and T-cell engagers, ensuring that observed antitumor effects are specifically driven by the intended tumor-associated antigen.

Other names

anti-tetanus toxoid bindernull targeted TriNKET binder